EU Approves Roche Drug Columvi For Lymphoma Treatment

2025-04-14 02:11:09

(MENAFN- Swissinfo) The European Commission has approved Roche's Columvi as the first bispecific antibody for the treatment of diffuse large B-cell lymphoma after initial therapy, the pharmaceutical giant announced on Monday. This content was published on April 14, 2025 - 11:51 2 minutes Keystone-SDA

Italiano it Roche: Ue approva Columvi per trattamento linfoma Original Read more: Roche: Ue approva Columvi per trattamento linfom

+Get the most important news from Switzerland in your inbox

The approval is based on the result of the phase III Starglo trial, during which Columvi – combined with Gemcitabine and oxaliplatin (GemOx) – demonstrated a“statistically and clinically significant improvement in survival” compared to other treatments, Roche explained.

+ How drug prices are negotiated in Switzerland and beyond

Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) is an aggressive cancer with a high risk of progression, which means that urgent and effective treatments are needed. In primary analyses, a 41% reduction in the risk of death was found among patients treated with Columvi and GemOx.

Translated from Italian by DeepL/ts

How we work

We select the most relevant news for an international audience and use automatic translation tools such as DeepL to translate them into English. An editor then briefly reviews the translation for clarity and accuracy before publication. Providing you with automatically translated news gives us the time to write more in-depth articles. The news stories we select have been written and carefully fact-checked by an external editorial team from news agencies such as Bloomberg or Keystone.
Did you find this explanation helpful? Please fill out this short survey to help us understand your needs: External link

Popular Stories More Workplace Switzerland Trump tariff shock: how Switzerland is positioning itself Read more: Trump tariff shock: how Switzerland is positioning itsel

MENAFN14042025000210011054ID1109428439

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.